A validated LC-MS/MS method for the rapid quantification of vilazodone in rat plasma: Application to a pharmacokinetic study

Journal of Pharmaceutical and Biomedical Analysis

Volumn 98, Issue , 2014, Pages 228-234

  Sui, Wenwen ^a   Yang, Xiaojing ^a   Yu, Wenhong ^a   Jin, Yi ^a   Luan, Xinyi ^a   Wang, Xiangjun ^a   Xu, Haiyan ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

LC MS MS; Pharmacokinetics; Rat plasma; Turboionspray ionization; Vilazodone

Indexed keywords

ACETONITRILE; AMMONIUM ACETATE; ESCITALOPRAM; FORMIC ACID; VILAZODONE; BENZOFURAN DERIVATIVE; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE;

ACCURACY; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; FLOW RATE; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; ANIMAL; BLOOD; CHEMISTRY; PLASMA; PROCEDURES; REPRODUCIBILITY; WISTAR RAT;

ANIMALS; BENZOFURANS; CHROMATOGRAPHY, LIQUID; INDOLES; MALE; PIPERAZINES; PLASMA; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 84902509302     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2014.05.034     Document Type: Article

References (20)

1. Lindsey W.T. Vilazodone for the treatment of depression. Ann. Pharmacother. 2011, 45:946-953.
2. Singh M., Schwartz T.L. Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use. Neuropsychiatr. Dis. Treat. 2012, 8:123-130.
3. Khan A. Vilazodone a novel dual-acting serotonergic antidepressant for managing major depression. Expert Opin. Investig. Drugs 2009, 18:1753-1764.
4. Dawson L.A., Watson J.M. Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS Neurosci. Ther. 2009, 15:107-117.
5. Citrome L. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newlyapproved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. Int. J. Clin. Pract. 2012, 66:356-368.
6. Forest Pharmaceuticals, Inc. Viibryd (Vilazodone) Prescribing Information 2011, April, http://www.frx.com/pi/viibryd_pi.pdf (accessed 17.10.11).
7. Laughren T.P., Gobburu J., Temple R.J., Unger E.F., Bhattaram A., Dinh P.V., Fossom L., Hung H.M., Klimek V., Lee J.E., Levin R.L., Lindberg C.Y., Mathis M., Rosloff B.N., Wang S.J., Wang Y., Yang P., Yu B., Zhang H., Zhang L., Zineh I. Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant. J. Clin. Psychiatry 2011, 72:1166-1173.
8. Choi E., Zmarlicka M., Ehret M.J. Vilazodone: a novel antidepressant. Am. J. Health Syst. Pharm. 2012, 69:1551-1557.
9. Frampton J.E. Vilazodone: in major depressive disorder. CNS Drugs 2011, 25:615-627.
10. Schwartz T.L., Siddiqui U.A., Stahl S.M. Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor. Ther. Adv. Psychopharmacol. 2011, 1:81-87.
11. Boinpally R., Alcorn H., Adams M.H., Longstreth J., Edwards J. Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment. Clin. Drug Investig. 2013, 33:199-206.
12. Reddy B.P., Pramod N., Venkateswararao P., Sudhakar babu A.M.S. Method development and validation for the assay of vilazodone in bulk and formulation by using RP-HPLC technique. Int. J. Biol. Pharm. Res. 2012, 3:789-795.
13. Yuan H., Ahasan M., Grill A., Desai-Krieger D. Application of differential mobility spectrometry (DMS) for the quantification of vilazodone and its carboxylic acid metabolite. American Society for Mass Spectrometry Conference 2012.
14. US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), Centre for Veterinary Medicine (CVM) Guidance for Industry, Bionanlytical Method Validation 2001, Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.
15. Bansal S., DeStefano A. Key elements of bioanalytical method validation for small molecules. AAPS J. 2007, 9:E109-E114.
16. Rainville P.D., Smith N.W., Cowan D., Plumb R.S. Comprehensive investigation of the influence of acidic, basic, and organic mobile phase compositions on bioanalytical assay sensitivity in positive ESI mode LC/MS/MS. J Pharm. Biomed. Anal. 2012, 59:138-150.
17. Viswanathan C.T., Bansal S., Booth B., DeStefano A.J., Rose M.J., Sailstad J., Shah V.P., Skelly J.P., Swann P.G., Weiner R. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assay. AAPS J. 2007, 9:E30-E42.
18. Fast D.M., Kelley M., Viswanathan C.T., O'Shaughnessy J., King S.P., Chaudhary A., Weiner R., DeStefano A.J., Tang D. Workshop report and follow-up - AAPS Workshop on current topics in GLP bioanalysis: assay reproducibility for incurred samples - implications of Crystal City recommendations. AAPS J. 2009, 11:238-241.
19. European Medicines Agency Guideline on Validation of Bioanalytical Methods 2011, Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf.
20. US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), Centre for Veterinary Medicine (CVM) Guidance for Industry, Bionanlytical Method Validation 2013, Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregu-latoryinformation/guidances/ucm368107.pdf.